ARS Pharmaceuticals (SPRY) Common Equity (2020 - 2026)

ARS Pharmaceuticals has disclosed Common Equity across 7 years of filings, most recently posting $61.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $61.3 million, down 73.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.3 million (down 73.22% YoY), and the FY2025 annual result was $114.3 million, down 55.51% from the prior year.
• Common Equity came in at $61.3 million for Q1 2026 at ARS Pharmaceuticals, down from $114.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $272.9 million in Q4 2022 to a low of -$50.2 million in Q3 2022.
• The 5-year median for Common Equity is $215.2 million (2024), against an average of $162.3 million.
• Peak annual rise in Common Equity reached 972.7% in 2022, while the deepest fall reached 115.1% in 2022.
• ARS Pharmaceuticals' Common Equity stood at $272.9 million in 2022, then retreated by 15.44% to $230.8 million in 2023, then advanced by 11.28% to $256.8 million in 2024, then sank by 55.51% to $114.3 million in 2025, then sank by 46.34% to $61.3 million in 2026.
• The last three Common Equity figures came in at $61.3 million (Q1 2026), $114.3 million (Q4 2025), and $147.7 million (Q3 2025), per Business Quant data.